Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer

• Status: Completed
• Trial end date: 2004-07-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining chemotherapy with peripheral stem cell transplantation in treating children who have central nervous system cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Roswell Park Cancer Institute
• Treatments: Carboplatin; Etoposide

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed primary central nervous system malignancy

• Recurrent, persistent, or progressive disease after at least 1 prior first-line treatment regimen

PATIENT CHARACTERISTICS:

Age

• 18 and under at initial diagnosis

Performance status

• ECOG 0-2

Life expectancy

• At least 8 weeks

Hematopoietic

• Absolute neutrophil count greater than 750/mm^3

• WBC greater than 2,500/mm^3

• Platelet count greater than 100,000/mm^3

• No underlying myelodysplasia, stem cell disorder, or other inherent hematologic synthetic defect

Hepatic

• Liver function tests less than 2 times normal OR

• Absence of active hepatitis by liver biopsy

• Bilirubin less than 1.5 mg/dL

Renal

• Glomerular filtration rate greater than 60 mL/min by radionucleotide assay

Cardiovascular

• Ejection fraction at least 45%

Pulmonary

• Clinically normal pulmonary function (patients 5 years of age and under)

• FEV_1 and FVC at least 50% (patients over 5 years of age) OR

• Arterial blood gas normal and DLCO greater than 50%

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No mucositis or mucosal infection

• HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• At least 3 weeks since prior systemic cytotoxic chemotherapy

Endocrine therapy

• Not specified

Radiotherapy

• At least 6 months since prior radiotherapy to the pelvis or spine

Surgery

• Not specified